Morgan Stanley
LEGN icon

Morgan Stanley’s Legend Biotech LEGN Stock Holding History

Morgan Stanley’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.3M Buy
1,394,531
+791,284
+131% +$21.3M ﹤0.01% 2449
2026
Q1 		$10.9M Buy
603,247
+120,697
+25% +$2.3M ﹤0.01% 3499
2025
Q4 		$10.5M Buy
482,550
+51,474
+12% +$1.47M ﹤0.01% 3569
2025
Q3 		$14.1M Sell
431,076
-87,213
-17% -$3.22M ﹤0.01% 3239
2025
Q2 		$18.4M Sell
518,289
-613,827
-54% -$19.9M ﹤0.01% 2895
2025
Q1 		$38.4M Buy
1,132,116
+599,159
+112% +$21.5M ﹤0.01% 2054
2024
Q4 		$17.3M Buy
532,957
+117,457
+28% +$4.87M ﹤0.01% 2897
2024
Q3 		$20.2M Buy
415,500
+40,280
+11% +$2.15M ﹤0.01% 2791
2024
Q2 		$16.6M Buy
375,220
+33,187
+10% +$1.53M ﹤0.01% 2868
2024
Q1 		$19.2M Sell
342,033
-548,454
-62% -$33.1M ﹤0.01% 2747
2023
Q4 		$53.6M Buy
890,487
+92,842
+12% +$5.88M ﹤0.01% 1657
2023
Q3 		$53.6M Sell
797,645
-90,717
-10% -$6.3M 0.01% 1506
2023
Q2 		$61.3M Buy
888,362
+459,610
+107% +$30M 0.01% 1417
2023
Q1 		$20.7M Buy
428,752
+163,436
+62% +$7.99M ﹤0.01% 2380
2022
Q4 		$13.2M Buy
265,316
+25,338
+11% +$1.23M ﹤0.01% 2780
2022
Q3 		$9.79M Buy
239,978
+87,013
+57% +$4.08M ﹤0.01% 3004
2022
Q2 		$8.41M Buy
152,965
+17,427
+13% +$736K ﹤0.01% 3245
2022
Q1 		$4.93M Sell
135,538
-21,485
-14% -$849K ﹤0.01% 3702
2021
Q4 		$7.32M Sell
157,023
-32,268
-17% -$1.64M ﹤0.01% 3309
2021
Q3 		$9.57M Buy
189,291
+131,584
+228% +$5.48M ﹤0.01% 2940
2021
Q2 		$2.37M Buy
57,707
+10,161
+21% +$345K ﹤0.01% 4505
2021
Q1 		$1.38M Sell
47,546
-65,919
-58% -$1.8M ﹤0.01% 4526
2020
Q4 		$3.19M Buy
113,465
+89,784
+379% +$2.58M ﹤0.01% 3746
2020
Q3 		$731K Sell
23,681
-5,977
-20% -$201K ﹤0.01% 4428
2020
Q2 		$1.26M Buy
+29,658
New +$1.16M ﹤0.01% 3987

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Morgan Stanley's LEGN Position: Q2 2026 in Review

Morgan Stanley increased its Legend Biotech (LEGN) stake by 131% in Q2 2026, buying an estimated $21.3M and bringing the position to 1,394,531 shares worth $40.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2449.

Morgan Stanley first reported a position in LEGN in Q2 2020 and has held it in 25 quarters since. The position peaked at $61.3M in Q2 2023. 218 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • Morgan Stanley held 1,394,531 shares of Legend Biotech worth $40.3M as of Q2 2026.
  • Morgan Stanley bought 791,284 Legend Biotech shares in Q2 2026, an estimated $21.3M.
  • Legend Biotech made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #2449 holding.
  • Morgan Stanley first reported a position in Legend Biotech in Q2 2020 and has held it in 25 quarters since.
  • Morgan Stanley's Legend Biotech position peaked at $61.3M in Q2 2023.
  • 218 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.